psalexa
logo

Neurofibromatoses Therapeutics - Pipeline Analysis 2018

Neurofibromatosis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: January 2018
Report Code: LS11248
Available Format:
Pages: 128

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.1.1 Types of Neurofibromatosis

4.2 Causes and Symptoms

4.3 Diagnosis

4.3.1 NF1 Diagnosis

4.3.2 NF2 Diagnosis

4.4 Prognosis

4.5 Prevention

4.6 Treatment

4.7 Epidemiology

4.8 Key Drivers

4.8.1 XXX

4.9 Key Barriers

4.9.1 Overlapping of NF with Many RAS-Driven Disorders

4.9.2 XXX

4.10 Neurofibromatosis Therapeutics Pipeline Analysis

4.10.1 Pipeline Analysis by Phase

4.10.2 Pipeline Analysis by Molecule Type

4.10.3 Pipeline Analysis by Route of Administration

4.10.4 Pipeline Analysis by Company

Chapter 5. Neurofibromatosis (NF) Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase II

5.1.1 Selumetinib

5.1.1.1 Clinical trial

5.1.1.2 Clinical trial results

5.1.1.3 Strategic development

5.1.2 Everolimus

5.1.2.1 Clinical trial

5.1.2.2 Clinical trial results

5.1.3 Lapatinib

5.1.3.1 Clinical trial

5.1.3.2 Clinical trial results

5.1.4 XXX

5.1.4.1 Clinical trial

5.1.5 XXX

5.1.5.1 Clinical trial

5.1.6 XXX

5.1.6.1 Clinical trial

5.1.7 XXX

5.1.7.1 Clinical trial

5.1.8 XXX

5.1.8.1 Clinical trial

5.1.9 XXX

5.1.9.1 Clinical trial

5.1.9.2 Clinical trial results

5.1.10 XXX

5.1.10.1 Strategic development

5.1.11 XXX

5.1.11.1 Strategic development

5.1.12 XXX

5.1.12.1 Clinical trial

5.1.12.2 Clinical trial results

5.1.12.3 Strategic development

5.1.13 XXX

5.1.13.1 Clinical trial

5.1.14 XXX

5.1.14.1 Clinical trial

5.1.15 XXX

5.1.15.1 Clinical trial

5.2 Phase I/II

5.2.1 XXX

5.3 Phase 0

5.3.1 AR42

5.3.1.1 Clinical trials

5.3.1.2 Strategic development

5.3.2 XXX

5.3.2.1 Clinical trials

5.4 Pre-Clinical

5.4.1 LB201

5.4.1.1 Strategic development

5.4.2 LB205

5.4.3 XXX

5.4.3.1 Strategic development

5.4.4 XXX

5.4.4.1 Pre-Clinical result

5.4.4.2 Strategic development

5.5 Discovery

5.5.1 Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for NF Type 2

5.5.1.1 Strategic development

5.5.2 XXX

5.5.3 XXX

5.5.3.1 Strategic development

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for NF Therapeutics Pipeline

7.2 SWOT Analysis of Neurofibromatosis Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Recursion Pharmaceuticals Inc.

8.1.1 Business Overview

8.1.2 Product and Service Offerings

8.2 Array BioPharma Inc.

8.2.1 Business Overview

8.2.2 Product and Service Offerings

8.3 Company 3

8.3.1 Business Overview

8.3.2 Product and Service Offerings

8.4 Company 4

8.4.1 Business Overview

8.4.2 Product and Service Offerings

8.5 Company 5

8.5.1 Business Overview

8.5.2 Product and Service Offerings

8.6 Company 6

8.6.1 Business Overview

8.6.2 Product and Service Offerings

8.7 Company 7

8.7.1 Business Overview

8.7.2 Product and Service Offerings

8.8 Company 8

8.8.1 Business overview

8.8.2 Product and Service Offerings

8.9 Company 9

8.9.1 Business Overview

8.9.2 Product and Service Offerings

8.10 Company 10

8.10.1 Business Overview

8.10.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

LIST OF TABLES

 

COMPARATIVE FEATURES OF NF1, NF2 AND SCHWANNOMATOSIS

PIPELINE ANALYSIS OF NEUROFIBROMATOSIS THERAPEUTICS, BY COMPANY (2018)

DESCRIPTION OF SELUMETINIB

CLINICAL TRIALS OF SELUMETINIB

DOSE-LIMITING TOXIC EFFECTS OF SELUMETINIB AND RESPONSE EVALUATION

DESCRIPTION OF EVEROLIMUS

CLINICAL TRIALS OF EVEROLIMUS

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

DESCRIPTION OF XXX

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

PHASE II STUDY DESIGN OF XXX IN CHILDREN AND ADULTS

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF XXX

DESCRIPTION OF AR42

CLINICAL TRIALS OF AR42

DESCRIPTION OF XXX

CLINICAL TRIALS OF XXX

DESCRIPTION OF LB201

DESCRIPTION OF LB205

DESCRIPTION OF XXX

DESCRIPTION OF XXX

DESCRIPTION OF SMALL MOLECULE TO INHIBIT HSP90-ALPHA AND TRAP1 FOR NF TYPE 2

DESCRIPTION OF DRUG FOR XXX

DESCRIPTION OF XXX

RECURSION PHARMACEUTICALS INC. - AT A GLANCE

ARRAY BIOPHARMA INC. - AT A GLANCE

COMPANY 3 - AT A GLANCE

COMPANY 4 - AT A GLANCE

COMPANY 5 - AT A GLANCE

COMPANY 6 - AT A GLANCE

COMPANY 7 - AT A GLANCE

COMPANY 8 - AT A GLANCE

COMPANY 9 - AT A GLANCE

COMPANY 10 - AT A GLANCE

 

LIST OF FIGURES

RESEARCH METHODOLOGY

BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

TYPES OF NEUROFIBROMATOSIS

CLINICAL DIAGNOSIS OF NEUROFIBROMATOSIS

NEUROFIBROMATOSIS DRUG CANDIDATES IN DEVELOPMENT (2018)

NEUROFIBROMATOSIS PIPELINE SPLIT, BY MOLECULE TYPE (2018)

NEUROFIBROMATOSIS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

MEAN PLASMA CONCENTRATION–TIME AND MEDIAN PHARMACOKINETIC RESULTS OF SELUMETINIB FOR THE THREE DOSE LEVELS

RESPONSE EVALUATION OF SELUMETINIB

INHIBITION OF KIT SIGNALING BY XXX

EFFECTS OF XXX ON SCF-INDUCED KIT ACTIVATION AND SIGNALING IN H526 SMALL CELL LUNG CANCER CELLS

EFFECTS OF XXX ON SCF-INDUCED KIT PHOSPHORYLATION IN CHO CELLS EXPRESSING WILD-TYPE KIT

EFFECTS OF XXX ON DEGRANULATION IN THE MAST CELL LINE LAD2

XXX INHIBITS SCF-INDUCED SECRETION OF TNFΑ AND GM-CSF IN THE LAD2 MAST CELL LINE

CROSS-REACTIVITY WITH KIT FROM VARIOUS SPECIES

SUBSTANTIAL DECREASE IN MAST CELL

BREAKDOWN OF CLINICAL TRIALS, BY REGION

BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

KEY PLAYERS BENCHMARKING

SWOT ANALYSIS

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry